George Kemble sold $3.6M of SGMT
Executive Chairman at Sagimet Biosciences Inc.. 350,987 shares at an average of $10.23, traded Aug 14, 2026, filed Aug 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.6M at market
- +20Share of holdings soldSold 85% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-354018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | MOption exercise Series A Common Stock10b5-1 | +326,618 | $6.36 | $2.1M | 388,779 | Aug 17, 2026 |
| Aug 14, 2026 | MOption exercise Series A Common Stock10b5-1 | +24,369 | $6.36 | $155k | 413,148 | Aug 17, 2026 |
| Aug 14, 2026 | SOpen-market sale Series A Common Stock10b5-1 | -350,987 | $10.23 | $3.6M | 62,161 | Aug 17, 2026 |
| Aug 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -326,618 | $0.00 | $0 | 31,455 | Aug 17, 2026 |
| Aug 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,369 | $0.00 | $0 | 11,608 | Aug 17, 2026 |
Related signals
Other insiders at Sagimet Biosciences Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Sagimet Biosciences Inc. | George Kemble Executive Chairman | $201k 20,206 shares | -25% | |
| 58Moderate | Sagimet Biosciences Inc. | David Happel President & CEO | $497k 64,051 shares | -8% | |
| 26Weak | Sagimet Biosciences Inc. | George Kemble Executive Chairman | $141k 18,844 shares | -23% | |
| 39Weak | Sagimet Biosciences Inc. | Elizabeth Rozek Chief Legal & Admin. Officer | $82k 10,545 shares | -4% | |
| 37Weak | Sagimet Biosciences Inc. | Thierry Chauche Chief Financial Officer | $7,033 1,312 shares | -8% | |
| 48Moderate | Sagimet Biosciences Inc. | David Happel President & CEO | $65k 12,101 shares | -2% | |
| 30Weak | Sagimet Biosciences Inc. | Eduardo Bruno Martins Chief Medical Officer | $20k 3,640 shares | -3% | |
| 30Weak | Sagimet Biosciences Inc. | Elizabeth Rozek Chief Legal & Admin. Officer | $14k 2,622 shares | -1% | |
| 24Weak | Sagimet Biosciences Inc. | George Kemble Executive Chairman | $290k 37,688 shares | -32% | |
| 59Moderate | Sagimet Biosciences Inc. | David Happel President & CEO | $598k 65,478 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.